An update on non-peptide angiotensin receptor antagonists and related RAAS modulators
about
Development of a novel 96-microwell assay with high throughput for determination of olmesartan medoxomil in its tabletsBinding of losartan to angiotensin AT1 receptors increases dopamine D1 receptor activationAntihypertensive treatment differentially affects vascular sphingolipid biology in spontaneously hypertensive ratsSafety and efficacy of fimasartan in patients with arterial hypertension (Safe-KanArb study): an open-label observational studyValsartan combination therapy in the management of hypertension - patient perspectives and clinical utilityTwo selective HPTLC methods for determination of some angiotensin II receptor antagonists in tablets and biological fluids.Therapeutic inhibition of the renin angiotensin aldosterone system.Valsartan plus hydrochlorothiazide for first-line therapy in hypertension.Elevation of the antifibrotic peptide N-acetyl-seryl-aspartyl-lysyl-proline: a blood pressure-independent beneficial effect of angiotensin I-converting enzyme inhibitorsThe biological significance of angiotensin-converting enzyme inhibition to combat kidney fibrosis.Evidence to Consider Angiotensin II Receptor Blockers for the Treatment of Early Alzheimer's Disease.Mechanistic Pathways in Amide Activation: Flexible Synthesis of Oxazoles and Imidazoles.Renin-angiotensin system as a potential target for new therapeutic approaches in Parkinson's disease.Divergent Spatiotemporal Interaction of Angiotensin Receptor Blocking Drugs with Angiotensin Type 1 Receptor.Olmesartan ameliorates urinary dysfunction in the spontaneously hypertensive rat via recovering bladder blood flow and decreasing oxidative stress.Effects of direct renin inhibition versus angiotensin II receptor blockade on angiotensin profiles in non-diabetic chronic kidney disease
P2860
Q28396474-716ECC28-1830-42FF-A60B-6623E19047DEQ28565562-1C57E3B4-E3C6-4EBC-905B-253670B1BF45Q34110842-644C45C8-4CB9-45E3-967D-C535AFDF7705Q34647575-EC3001BE-39CE-43F9-BB0B-C9246E801DFFQ35210583-09F209CA-E9C8-4585-A4C7-CE825A478BF2Q36220469-38C38691-67E6-450E-81D4-1F42B7A7DD24Q37489951-C650BE1B-7320-4AF5-BCD2-D093D5C729F9Q37642814-19EBEFE4-A97B-462C-BFED-6CC3E84E2CA8Q37962590-55A3A905-27F4-4F94-8091-0440C26D4EC5Q38224257-9DC4F12C-4C8F-44F4-BA39-2BCF284011FBQ38781028-8FA826A6-3683-4953-8C04-639586CBE143Q41110549-1894CAF2-A2F1-4211-A46F-AF380BA618B4Q46316918-78849057-9193-46E3-B9C5-8DACCE86BB68Q47383912-C5E2348C-8EB8-490E-A72C-5915B0003E91Q50899540-5D882BB7-DBCA-48A4-8EED-0EFCBF456DB9Q58269559-633971A4-CD38-47B3-A3A0-8671FCBC562E
P2860
An update on non-peptide angiotensin receptor antagonists and related RAAS modulators
description
2007 nî lūn-bûn
@nan
2007 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
An update on non-peptide angiotensin receptor antagonists and related RAAS modulators
@ast
An update on non-peptide angiotensin receptor antagonists and related RAAS modulators
@en
An update on non-peptide angiotensin receptor antagonists and related RAAS modulators
@nl
type
label
An update on non-peptide angiotensin receptor antagonists and related RAAS modulators
@ast
An update on non-peptide angiotensin receptor antagonists and related RAAS modulators
@en
An update on non-peptide angiotensin receptor antagonists and related RAAS modulators
@nl
prefLabel
An update on non-peptide angiotensin receptor antagonists and related RAAS modulators
@ast
An update on non-peptide angiotensin receptor antagonists and related RAAS modulators
@en
An update on non-peptide angiotensin receptor antagonists and related RAAS modulators
@nl
P1433
P1476
An update on non-peptide angiotensin receptor antagonists and related RAAS modulators
@en
P2093
P304
P356
10.1016/J.LFS.2007.06.007
P407
P577
2007-06-28T00:00:00Z